Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)

Απλή σελίδα τεκμηρίου
dc.contributor.authorPavlidis, N.en
dc.contributor.authorAamdal, S.en
dc.contributor.authorAwada, A.en
dc.contributor.authorCalvert, H.en
dc.contributor.authorFumoleau, P.en
dc.contributor.authorSorio, R.en
dc.contributor.authorPunt, C.en
dc.contributor.authorVerweij, J.en
dc.contributor.authorvan Oosterom, A.en
dc.contributor.authorMorant, R.en
dc.contributor.authorWanders, J.en
dc.contributor.authorHanauske, A. R.en
dc.date.accessioned2015-11-24T19:31:32Z
dc.date.available2015-11-24T19:31:32Z
dc.identifier.issn0344-5704-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23282
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents/administration & dosage/adverse effects/*therapeutic useen
dc.subjectBenzofurans/administration & dosage/adverse effects/*therapeutic useen
dc.subjectBreast Neoplasms/drug therapyen
dc.subjectColorectal Neoplasms/drug therapyen
dc.subjectFemaleen
dc.subjectHead and Neck Neoplasms/drug therapyen
dc.subjectHumansen
dc.subjectIndoles/administration & dosage/adverse effects/*therapeutic useen
dc.subjectInfusions, Intravenousen
dc.subjectLymphoma, Non-Hodgkin/drug therapyen
dc.subjectMaleen
dc.subjectMelanoma/drug therapyen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectNeoplasms/*drug therapy/pathologyen
dc.subjectOvarian Neoplasms/drug therapyen
dc.subjectProdrugs/adverse effects/*therapeutic useen
dc.subjectStomach Neoplasms/drug therapyen
dc.titleCarzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)en
heal.abstractPURPOSE: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. PATIENTS AND METHODS: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma. The drug was given as a bolus infusion at a 4-weekly dose of 150 microg/m2. A total of 140 patients were entered and a total of 285 courses were administered. RESULTS: In general, the compound was well tolerated. Myelotoxicity was the most common toxicity. Grade 3 and 4 leukopenia was observed in 18.6% of the courses, neutropenia in 20.3%, thrombocytopenia in 16.2% and anemia in 8.7%. Double nadirs were seen in a total of 41 courses for neutrophils, in 40 for leukocytes and in 3 for platelets. Non-hematological toxicity was very mild. Only one partial response in a patient with melanoma was seen. CONCLUSIONS: At this dose and schedule carzelesin did not yield activity in the types of tumors studied.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10972487-
heal.identifier.secondaryhttp://www.springerlink.com/content/8um0pnej4jhdwdtn/fulltext.pdf-
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ